Treat parvo. Fight parvo. Stop parvo.

Canine Parvovirus Monoclonal Antibody is the FIRST and ONLY USDA conditionally approved monoclonal antibody treatment that targets canine parvovirus.

Order Now Learn More

Parvo Kills

While canine parvovirus (CPV) vaccinations are highly effective and widely available, CPV is still a real and ever-present threat to all dogs, with unvaccinated and young puppies the most at risk.

Canine Parvovirus Monoclonal Antibody (CPMA) is finally here.

Fight parvo with Canine Parvovirus Monoclonal Antibody

With just one intravenous dose, Canine Parvovirus Monoclonal Antibody (CPMA) may shorten the course of the disease and improve outcomes.

Targets parvovirus directly
Single-dose efficacy
High safety profile
Can decrease burden of supportive care
Can reduce emotional stress

Well tolerated in puppies as young as 6 weeks of age.¹

Two components. One powerful product.

CPMA is composed of a dog constant region and a rat variable region. These two elements work together to neutralize canine parvovirus in vivo by selectively binding and blocking the virus from entering and destroying enterocytes.

Targeted Efficacy

After challenged with virulent CPV-2b, zero dogs died when treated with Canine Parvovirus Monoclonal Antibody.¹

Canine Parvovirus Monoclonal Antibody Resources

Parvo is Poop Open Letter

Read Now

CPMA-treated parvo survivor, Aiden

(2 months), PAWS Chicago

Parvo kills. Now you can fight back and get rewarded.

The Defenders Fund established by Elanco provides up to $1 million to help increase the availability of the life-saving USDA-conditionally approved Canine Parvovirus Monoclonal Antibody treatment in local clinics across the country.

With every carton purchased, clinics earn a $25 rebate. If clinics share a canine parvovirus survivor story with us, then they will earn an additional $25 rebate per success story submitted. Clinics can track their savings by registering on myElanco.

Share Story